A Phase 2, Randomized, Double-blind, Placebo Controlled, Single Dose-level, Proof-of-concept Study Evaluating FP-101 for the Treatment of Vasomotor Symptoms in Postmenopausal Women
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs FP-101 (Primary)
- Indications Hot flashes
- Focus Proof of concept; Therapeutic Use
- Sponsors Fervent Pharmaceuticals
- 14 Feb 2018 Last checked against ClinicalTrials.gov record
- 08 Feb 2018 Planned End Date changed from 14 Aug 2018 to 10 Jan 2019.
- 08 Feb 2018 Planned primary completion date changed from 20 May 2018 to 21 Oct 2018.